Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3730-3738

  Meynet, Ophélie ^a,b   Scotlandi, Katia ^c   Pradelli, Emmanuelle ^a,b   Manara, Maria C ^c   Colombo, Mario P ^d   Schmid Antomarchi, Heidy ^a,b   Picci, Piero ^c   Bernard, Alain ^a,b   Bernard, Ghislaine ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c Laboratorio di Oncologia Sperimentale   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD99 ANTIGEN; PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; XG PROTEIN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GROUP XG SYSTEM; CANCER CELL CULTURE; CANCER INVASION; CANCER LOCALIZATION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION; XENOGRAFT;

ADOLESCENT; ANIMALS; BLOOD GROUP ANTIGENS; BONE NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROGNOSIS; SARCOMA, EWING'S;

EID: 77951736324     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2837     Document Type: Article

References (43)

1. Paulussen M, Bielack S, Jurgens H, Casali PG, On behalf of the EGWG. Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:iv140-2.
2. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-5754
3. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 2003;56:96-102.
4. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 2001;276:41977-41984
5. Castillero-Trejo YES, Xiang L, Richardson JA, Ilaria RL. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005;65:8698-8705
6. Riggi NCL, Provero P, Suvà ML, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-11468
7. Tirode FL-DK, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11: 421-429 (Pubitemid 46680428)
8. Ambros IMAP, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;7:1886-1893
9. LLombart-Bosch A, Machado I, Navarro S, et al. Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch 2009;5:397-411.
10. Dworzak MNFG, Printz D, Zen LD, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 2004;18:703-708 (Pubitemid 38500188)
11. Hahn JHKM, Choi EY, Kim SH, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997;59:2250-2258
12. Alberti I, Bernard G, Rouquette-Jazdanian A, et al. CD99 isoforms expression dictates T cell Functional outcomes. FASEB J 2002;16: 1946-1948
13. Scotlandi K, Zuntini M, Manara MC, et al. CD99 isoforms dictate opposite functions in tumour malignacy and metastases by activating or repressing c-Src kinase activity. Oncogene 2007; 46:6604-6618 (Pubitemid 47573680)
14. Bremond A, Meynet O, Mahiddine K, et al. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood 2009;113:347-357
15. Bernard G, Alberti I, Pourtein M, Widjenes J, Ticchioni M, Bernard A. CD99 (E2) up-regulates α4β1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol 2000;30: 3061-3065
16. Schenkel ARMZ, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143-150 (Pubitemid 34141444)
17. Lou O, Alcaide P, Luscinskas FW, Muller WA. CD99 is a key mediator of the transendothelial migration of neutrophils. J Immunol 2007;178: 1136-1143 (Pubitemid 46095186)
18. Imbert A-M, Belaaloui G, Bardin F, et al. CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration. Blood 2006;108:2578-2586
19. Manara MCBG, Lollini PL, Nanni P, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006;17:1910-1921
20. Kreppel MAD, Schaefer KL, Amann G, Kofler R, Poremba C, Kovar H. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene 2006;25:2795-2800
21. Ellis NAYT, Patton S, German J, Goodfellow PN, Weller P. Cloning of PBDX, an MIC2-related gene that spans the pseudoautosomal boundary on chromosome Xp. Nat Genet 1994:394-400. (Pubitemid 24190025)
22. Suh YH, Shin YK, Kook MC, et al. Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene 2003;307:63-76.
23. Bixel MG, Petri B, Khandoga AG, et al. A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 2007;109:5327-5336 (Pubitemid 46890554)
24. Ellis NATP, Petty A, Reid M, et al. PBDX is the XG blood group gene. Nat Genet 1994;8:285-290
25. Mann JDCA, Gelb AG, Fischer N, et al. A sex-linked blood group. Lancet 1962;1:8-10.
26. Goodfellow PNTP. A human quantitative polymorphism related to Xg blood groups. Nature 1981;289:404-405 (Pubitemid 11135148)
27. Van Valen F. Ewing's sarcoma Family of tumors. In: Masters JRW, Palsoon B, editors. Human cell culture, Cancer cell lines. 1999, p. 55-85.
28. Fouchet CGP, Cartron JP, Lopez C. Quantitative analysis of XG blood group and CD99 antigens on human red cells. Immunogenetics 2000;51:688-694 (Pubitemid 30447204)
29. Fouchet CGP, Huet M, Fellous M, et al. A study of the coregulation and tissue specificity of XG and MIC2 gene expression in eukaryotic cells. Blood 2000;95:1819-1826 (Pubitemid 30120848)
30. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45:469-475
31. Wiebe T, Wiklund T, Fossati Bellani F, et al. Presentation of an Italian-Scandinavian treatment protocol for non-metastatic (ISG/SSG III) and high risk Ewing's family tumors (ISG/SSG IV). Acta Orthop Scand 1999;70:28-29
32. Ferrari S, Alvegard T, Luksch R, et al. Non-metastatic Ewing's family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/ SSG III protocol. J Clin Oncol 2007 Suppl. Vol.25, 18S, p. 548, ASCO meeting, Chicago, US.
33. Cotterill SJAS, Paulussen M, Jürgens HF, Voûte PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114
34. Llombart-Bosch A, Contesso G, Henry-Amar M, et al. Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. A retrospective study of 261 cases. Virchows Archiv 1986;409:627-640
35. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-1769
36. Riley RD, Burchill SA, Abrams KR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 2003;39:19-30.
37. Manara MC, Perbal B, Benini S, et al. The Expression of ccn3(nov) Gene in Musculoskeletal Tumors. Am J Pathol 2002;160:849-859
38. De Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma [published erratum appears in J Clin Oncol 1998 Aug;16:2895]. J Clin Oncol 1998;16:1248-1255
39. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245-1251
40. De Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-792 (Pubitemid 30658577)
41. Matsunobu T, Tanaka K, Matsumoto Y, et al. The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin Cancer Res 2004;10:1003-1012
42. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004;23:8997-9006.
43. Scotlandi K, Remondini D, Castellani G, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009;27:2209-2216